Its also known to reduce the risk of adverse cardiovascular events such as stroke, heart attack, or death in people with type 2 diabetes and known heart disease
Chronic Rhinosinusitis with Nasal Polyps (incidence 1% in adult patients): injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis
Lucena, R
Not everyone on Semaglutide suffers from Ozempic face, but there are other concerns
LDM management is suitable for all skin types
Pfizer #Reports #Strong Phase 2b #Results for #Monthly #GLP-1 Candidate #Berobenatide, Advancing Broad Phase 3 Obesity Program Pfizer unveiled detailed Phase 2b data for berobenatide (PF-07976016/PF3944) at ADA 2026, highlighting the potential of what could become the first monthly GLP-1 receptor agonist peptide for obesity management